Methylated BNIP3 gene in colorectal cancer prognosis | Zendy

Sayaka Shimizu | Zendy; Satoru Iida | Zendy; Megumi Ishiguro | Zendy; Hiroyuki Uetake | Zendy; Toshiaki Ishikawa | Zendy; Yoko Takagi | Zendy; Hirotoshi Kobayashi | Zendy; Tetsuro Higuchi | Zendy; Masayuki Enomoto | Zendy; Kaoru Mogushi | Zendy; Hiroshi Mizushima | Zendy; Hiroshi Tanaka | Zendy; Kenichi Sugihara | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Methylated BNIP3 gene in colorectal cancer prognosis

Author(s) -

Sayaka Shimizu,

Satoru Iida,

Megumi Ishiguro,

Hiroyuki Uetake,

Toshiaki Ishikawa,

Yoko Takagi,

Hirotoshi Kobayashi,

Tetsuro Higuchi,

Masayuki Enomoto,

Kaoru Mogushi,

Hiroshi Mizushima,

Hiroshi Tanaka,

Kenichi Sugihara

Publication year - 2010

Publication title -

oncology letters

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.766

H-Index - 54

eISSN - 1792-1082

pISSN - 1792-1074

DOI - 10.3892/ol_00000153

Subject(s) - methylation , irinotecan , dna methylation , colorectal cancer , cancer research , apoptosis , oncogene , biology , cancer , microarray analysis techniques , microarray , gene , oncology , cell cycle , medicine , gene expression , genetics

The DNA methylation of apoptosis-related genes in various cancers contributes to the disruption of the apoptotic pathway and results in resistance to chemotherapeutic agents. Irinotecan (CPT-11) is one of the key chemotherapy drugs used to treat metastatic colorectal cancer (CRC). However, a number of metastatic CRC patients do not benefit from this drug. Thus, the identification of molecular genetic parameters associated with the response to CPT-11 is of interest. To identify apoptosis-related genes that may contribute to CPT-11 resistance, microarray analysis was conducted using colon cancer cells in which 5-aza-2'deoxycytidine (DAC) enhanced sensitivity to CPT-11. Microarray analysis identified 10 apoptosis-related genes that were up-regulated following treatment with DAC. Among the genes, Bcl-2/adenovirus E1B 19 kDa protein interacting protein 3 (BNIP3), a Bcl-2 family pro-apoptotic protein, was identified as being involved in CPT-11 resistance following methylation of its promoter. An analysis of 112 primary CRC cases revealed that approximately 58% of cases showed BNIP3 methylation, and that patients with methylation exhibited a poorer outcome compared to those without methylation. In addition, in 30 patients who received first-line CPT-11 chemotherapy, patients with methylation exhibited resistance to chemotherapy compared to patients with no methylation. The results suggest that methylation of BNIP3 is a predictive factor in the prognosis and response to CPT-11 treatment in CRC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research